Abstract
Introduction: Central venous catheters (CVC) are employed to manage patients with severe bleeding disorders. However, up to 50% of these children may develop CVC-related deep vein thrombosis (CVC-DVT). Due to the high risk of CVC-DVT, in 2001 we instituted a DVT screening program consisting of performing contrast venograms and Doppler sonograms every two years after CVC insertion and regular assessment for signs or symptoms of post-thrombotic syndrome (PTS). Identification of early vascular changes prompted transitioning of patients to peripheral vein (PV) access within the following 12 months. We now report the outcome of this screening program.
Methods: We reviewed all patients with inherited bleeding disorders who had CVCs placed during 2000–08. Data collected included CVC type, location, duration, associated complications, and imaging results. Examination findings of prominent chest wall veins and arm circumference discrepancies were also recorded. We evaluated the time to transition to PV infusions.
Results: Thirty-six patients were studied, of whom 28 had Factor VIII deficiency, 6 Factor IX deficiency, and 2 severe von Willebrand disease. Thirty catheters were placed for prophylaxis and 7 for immune tolerance induction. One patient had 2 lines placed. Median age at line placement was 25 months. Catheters were inserted into the subclavian (n=15), external jugular (n=16), internal jugular (n=3), or facial vein (n=1); the site of 2 catheters is unknown. CVCs were in place a median of 41.3 ± 22.8 months. In 27 patients, the first venogram was performed at a median time of 25.5 months after placement. Of the other 9 patients (10 catheters), 5 catheters were in place ≤ 24 months, 1 CVC was removed without imaging, 2 patients transferred to other programs, 1 CVC was removed for infection within one month after placement, and 1 child died from sepsis with CVC in place (
Conclusion: Early screening identified a CVC-DVT incidence of 28% within 2 years and 36% within 4 years. Successful transition to PV infusion is usually possible within a year after vascular changes and before 5 years of CVC use. In addition, 69% of those with CVC-DVT had evidence of mild PTS. The late sequelae of CVC-DVT are unknown. Therefore, screening for DVT, early transition to PV, and long-term follow-up is essential when CVCs are used for children with inherited bleeding disorders.
Disclosures: Spencer:Wyeth Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees. Journeycake:Baxter Healthcare: Membership on an entity’s Board of Directors or advisory committees.
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal